📊 AIM Key Takeaways
Is AIM ImmunoTech Inc. (AIM) a Good Investment?
AIM ImmunoTech is a pre-revenue biotech company with minimal cash generation, burning $2.7M quarterly against only $22K in revenue. With $5.8M cash reserves and negative operating cash flow, the company faces a critical runway crisis within 2-3 periods absent significant financing or revenue development.
AIM ImmunoTech’s fundamentals are extremely weak: revenue is negligible at $67K while operating and free cash flow losses are near $9M, producing deeply negative margins that indicate the business is not commercially self-sustaining. The balance sheet is also distressed, with negative equity, liabilities exceeding assets, and sub-1.0 liquidity ratios, which raises significant going-concern and financing risk. While cash on hand provides some short-term flexibility, the overall financial profile points to very poor growth quality and high dependence on external capital.
AIM ImmunoTech Inc. Key Strengths (AIM)
- Net loss improving 19.4% YoY indicating cost management efforts
- Cash position of $5.8M provides near-term operational runway
- EPS loss reduced 72.1% YoY suggesting dilution control
- Cash and equivalents of $2.35M provide limited near-term operating flexibility
- Capital expenditure requirements are minimal, which reduces fixed reinvestment pressure
- EPS loss improved year over year, indicating some reduction in per-share loss pressure
AIM Stock Risks: AIM ImmunoTech Inc. Investment Risks
- Pre-revenue company burning $2.7M quarterly with only $22K in revenue creating imminent solvency crisis
- Dangerously tight current ratio of 1.01x and high debt-to-equity of 1.98x limit financial flexibility
- Cash runway of approximately 2-3 quarters at current burn rate without additional financing or revenue generation
- Revenue base is immaterial relative to operating costs, resulting in extreme negative operating and net margins
- Negative stockholders equity and liabilities above assets indicate a severely weakened balance sheet
- Operating cash flow and free cash flow are deeply negative, implying continued dependence on outside financing
Key Metrics to Watch
- Quarterly cash balance and burn rate trends
- Revenue and clinical pipeline progress updates
- Debt refinancing developments and capital raise announcements
- Quarterly cash burn relative to cash balance
- Any material increase in revenue versus operating expense base
AIM ImmunoTech Inc. (AIM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
AIM ImmunoTech Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AIM Profit Margin, ROE & Profitability Analysis
AIM vs Healthcare Sector: How AIM ImmunoTech Inc. Compares
How AIM ImmunoTech Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AIM ImmunoTech Inc. Stock Overvalued? AIM Valuation Analysis 2026
Based on fundamental analysis, AIM ImmunoTech Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AIM ImmunoTech Inc. Balance Sheet: AIM Debt, Cash & Liquidity
AIM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AIM ImmunoTech Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $-30.92 indicates the company is currently unprofitable.
AIM Revenue Growth, EPS Growth & YoY Performance
AIM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $16.0K | -$3.0M | $-0.05 |
| Q3 2025 | $26.0K | -$1.8M | $1.57 |
| Q2 2025 | $25.0K | -$1.8M | $-3.00 |
| Q1 2025 | $16.0K | -$3.7M | $-0.05 |
| Q3 2024 | $35.0K | -$3.7M | $-0.06 |
| Q2 2024 | $42.0K | -$1.8M | $-0.03 |
| Q1 2024 | $40.0K | -$3.7M | $-0.08 |
| Q3 2023 | $21.0K | -$6.4M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AIM ImmunoTech Inc. Dividends, Buybacks & Capital Allocation
AIM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AIM ImmunoTech Inc. (CIK: 0000946644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AIM
What is the AI rating for AIM?
AIM ImmunoTech Inc. (AIM) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AIM's key strengths?
Claude: Net loss improving 19.4% YoY indicating cost management efforts. Cash position of $5.8M provides near-term operational runway. ChatGPT: Cash and equivalents of $2.35M provide limited near-term operating flexibility. Capital expenditure requirements are minimal, which reduces fixed reinvestment pressure.
What are the risks of investing in AIM?
Claude: Pre-revenue company burning $2.7M quarterly with only $22K in revenue creating imminent solvency crisis. Dangerously tight current ratio of 1.01x and high debt-to-equity of 1.98x limit financial flexibility. ChatGPT: Revenue base is immaterial relative to operating costs, resulting in extreme negative operating and net margins. Negative stockholders equity and liabilities above assets indicate a severely weakened balance sheet.
What is AIM's revenue and growth?
AIM ImmunoTech Inc. reported revenue of $22.0K.
Does AIM pay dividends?
AIM ImmunoTech Inc. does not currently pay dividends.
Where can I find AIM SEC filings?
Official SEC filings for AIM ImmunoTech Inc. (CIK: 0000946644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AIM's EPS?
AIM ImmunoTech Inc. has a diluted EPS of $-0.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AIM's fundamental grade?
Based on our AI fundamental analysis in June 2026, AIM ImmunoTech Inc. has a D grade with 96% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AIM stock overvalued or undervalued?
Valuation metrics for AIM: ROE of -142.3% (sector avg: 15%), net margin of -13,740.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AIM's AI grade for 2026?
Our dual AI analysis gives AIM ImmunoTech Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AIM's free cash flow?
AIM ImmunoTech Inc.'s operating cash flow is $-2.7M, with capital expenditures of $18.0K. FCF margin is -12,440.9%.
How does AIM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -13,740.9% (avg: 12%), ROE -142.3% (avg: 15%), current ratio 1.01 (avg: 2).
Is AIM ImmunoTech Inc. carrying too much debt?
AIM has a debt-to-equity ratio of 1.98x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.01 suggests adequate short-term liquidity.